What did Rubicon pay for Horizon Infusions?

Rubicon acquired Horizon Infusions for $130.0M in 2025 (16.3x EBITDA). Target EBITDA was approximately $8.0M.

What does Horizon Infusions do?

Horizon Infusions is a pharmacy business.

What multiple did Rubicon pay for Horizon Infusions?

16.3x EBITDA, based on disclosed deal value of $130.0M and disclosed financials.

M&A TRANSACTION · 2025

Horizon Infusions acquired by Rubicon

$130.0M· 16.3x EBITDA

Target

Horizon Infusions

Acquirer

Rubicon

Disclosed financials at time of acquisition

Revenue

—

EBITDA

$8.0M

Deal Value

$130.0M

EV/EBITDA

16.3x

Context

This $130.0M acquisition of Horizon Infusions by Rubicon sits in the pharmacy sub-vertical. The 16.3x EBITDA multiple paid in 2025 can be compared against the population median for pharmacy transactions of similar size on our Pharmacy valuation hub.

Source

Data sourced from Press reporting. All figures reflect disclosed values at the time of the acquisition; no estimated or imputed data. Methodology

Value your own pharmacy

Get an instant valuation range for your business. Backed by 25,592 real M&A transactions.

Compare your business to the Horizon Infusions acquisition.

Citation: ExitValue.ai. (2025). Horizon Infusions acquired by Rubicon. https://exitvalue.ai/deals/horizon-infusions-acquired-by-rubicon-hc-2025-0016